NCT02793544 · OUTCOME
Cumulative Incidences of Viral Reactivations and Infections: Grade 2 HHV-6 Infection
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- percentage of participants
- Interval / dispersion
- 90% Confidence Interval
- Time frame
- 100 days, 180 days, 365 days
What was measured
Clinically active HHV-6 infection (e.g. symptoms, cytopenias) or HHV-6 viremia without viral load decline 0.5 log after 2 weeks of therapy). A cumulative incidence will be computed along with a 90% CI.
Groups in this outcome
Myeloablative Conditioning (MAC)
Participants received one of three regimens: cyclophosphamide and total body irradiation; busulfan and cyclophosphamide; or fludarabine and busulfan
Reduced Intensity Conditioning (RIC)
Participants received one of two regimens: fludarabine, cyclophosphamide, and low-dose total body irradiation
| Group | Source count |
|---|---|
| Myeloablative Conditioning (MAC) | 40 |
| Reduced Intensity Conditioning (RIC) | 39 |
Reported measurements
100 days
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Myeloablative Conditioning (MAC) | 12.5 | Not reported | 5.3 | 22.3 | Not reported |
| Reduced Intensity Conditioning (RIC) | 5.1 | Not reported | 0.9 | 12.4 | Not reported |
180 days
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Myeloablative Conditioning (MAC) | 12.5 | Not reported | 5.3 | 22.3 | Not reported |
| Reduced Intensity Conditioning (RIC) | 5.1 | Not reported | 0.9 | 12.4 | Not reported |
365 days
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Myeloablative Conditioning (MAC) | 12.5 | Not reported | 5.3 | 22.3 | Not reported |
| Reduced Intensity Conditioning (RIC) | 5.1 | Not reported | 0.9 | 12.4 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 5.3
- upper Limit
- 22.3
- value
- 12.5
- group Id
- OG001
- lower Limit
- 0.9
- upper Limit
- 12.4
- value
- 5.1
- title
- 100 days
- categories
- measurements
- group Id
- OG000
- lower Limit
- 5.3
- upper Limit
- 22.3
- value
- 12.5
- group Id
- OG001
- lower Limit
- 0.9
- upper Limit
- 12.4
- value
- 5.1
- title
- 180 days
- categories
- measurements
- group Id
- OG000
- lower Limit
- 5.3
- upper Limit
- 22.3
- value
- 12.5
- group Id
- OG001
- lower Limit
- 0.9
- upper Limit
- 12.4
- value
- 5.1
- title
- 365 days
- denoms
- counts
- group Id
- OG000
- value
- 40
- group Id
- OG001
- value
- 39
- units
- Participants
- description
- Clinically active HHV-6 infection (e.g. symptoms, cytopenias) or HHV-6 viremia without viral load decline 0.5 log after 2 weeks of therapy). A cumulative incidence will be computed along with a 90% CI.
- dispersion Type
- 90% Confidence Interval
- groups
- description
- Participants received one of three regimens: cyclophosphamide and total body irradiation; busulfan and cyclophosphamide; or fludarabine and busulfan
- id
- OG000
- title
- Myeloablative Conditioning (MAC)
- description
- Participants received one of two regimens: fludarabine, cyclophosphamide, and low-dose total body irradiation
- id
- OG001
- title
- Reduced Intensity Conditioning (RIC)
- param Type
- NUMBER
- reporting Status
- POSTED
- time Frame
- 100 days, 180 days, 365 days
- title
- Cumulative Incidences of Viral Reactivations and Infections: Grade 2 HHV-6 Infection
- type
- SECONDARY
- unit Of Measure
- percentage of participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle